Indore: The heartbreaking deaths linked to contaminated Coldrif cough syrup have uncovered serious cracks in pharmaceutical manufacturing standards, leading to a major regulatory crackdown. A pharmaceutical unit in Indore has now been ordered to temporarily stop production after more than 200 deficiencies were found against established standards. The joint inspection, conducted by the central and state government departments, took place in late September at the pharmaceutical unit operated by a private company in the Sanwer Road Industrial Area, said Chief Medical and Health Officer (CMHO) Dr Madhav Prasad Hasani. "During the inspection, 216 deficiencies were found against set standards in drug production and other processes. Following this, production at the unit has been halted until further orders. A show-cause notice has also been issued to the private company regarding these deficiencies," he said.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!